Travere Therapeutics Inc
General ticker "TVTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.4B
Travere Therapeutics Inc follows the US Stock Market performance with the rate: 51.7%.
Estimated limits based on current volatility of 2.4%: low 16.65$, high 17.45$
Factors to consider:
- Current price 33.2% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [5.63$, 12.87$]
- 2024-12-30 to 2025-12-30 estimated range: [7.02$, 14.62$]
Financial Metrics affecting the TVTX estimates:
- Negative: Non-GAAP EPS, $ of -4.73 <= 0.10
- Negative: Operating profit margin, % of -72.77 <= 1.03
- Negative: Operating cash flow per share per price, % of -32.31 <= 2.35
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
Short-term TVTX quotes
Long-term TVTX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $131.84MM | $109.46MM | $145.24MM |
| Operating Expenses | $331.26MM | $429.27MM | $533.38MM |
| Operating Income | $-199.43MM | $-319.81MM | $-388.14MM |
| Non-Operating Income | $-17.46MM | $-11.34MM | $12.03MM |
| Interest Expense | $20.14MM | $11.28MM | $11.33MM |
| R&D Expense | $210.33MM | $235.78MM | $244.99MM |
| Income(Loss) | $-216.88MM | $-331.15MM | $-376.11MM |
| Taxes | $0.41MM | $0.31MM | $0.22MM |
| Other Income(Loss) | $37.20MM | $52.99MM | $264.93MM |
| Profit(Loss) | $-180.09MM | $-278.48MM | $-111.40MM |
| Stockholders Equity | $302.11MM | $42.85MM | $200.81MM |
| Inventory | $7.31MM | $6.92MM | $9.41MM |
| Assets | $776.63MM | $672.59MM | $788.91MM |
| Operating Cash Flow | $-14.79MM | $-186.29MM | $-280.02MM |
| Capital expenditure | $24.15MM | $28.56MM | $0.67MM |
| Investing Cash Flow | $-137.62MM | $-32.55MM | $55.78MM |
| Financing Cash Flow | $231.68MM | $117.57MM | $218.75MM |
| Earnings Per Share* | $-3.01 | $-4.37 | $-1.50 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.